General Electric's Niskayuna, NY-based GE Global Research unit is teaming up with Celera Genomics Group and Celera Diagnostics to jointly research new products for what GE is calling "personalized medicine." The firms said they will seek to understand and differentiate disease at the molecular level, with an eye on developing new diagnostics and treatments tailored for specific diseases and/or patient populations.
The first project on the agenda is intended to support GE's development of imaging agents for cancer that selectively target cell surface proteins that Celera Genomics of Rockville, MD, has identified as being associated with cancer. These cell surface proteins are also the basis for complementary drug-discovery programs undertaken by Celera Genomics and its partners, according to the companies.
Under this project agreement, GE will gain exclusive access to selected protein targets for research and development of medical imaging agents. The parties will share certain responsibilities and costs associated with research and development, as well as value from commercial products resulting from the project, the firms said.
The second project relates to bioinformatics and supports the development of new algorithms and tools to advance the diagnostic and/or therapeutic programs of collaboration partners, according to the companies. New project agreements related to other disease areas or tools may be added in the future.
By AuntMinnie.com staff writersJuly 12, 2004
Related Reading
GE revenues, earnings surge in Q2, July 12, 2004
GE, Confirma partner on MR mammo CAD, July 1, 2004
GE installs first beta version of 64-slice scanner, June 29, 2004
GE upgrades Infinia, unveils 18F-F2 production activity, June 22, 2004
GE inks Italian RIS/PACS deal, May 4, 2004
Copyright © 2004 AuntMinnie.com
